Abstract
The AFFIRM study showed no clear survival advantage for a rhythm versus rate control strategy in patients with atrial fibrillation (AF). However, rhythm control with antiarrhythmic drugs (AADs) is appropriate in a large number of patients with AF. The American College of Cardiology/American Heart Association/European Society of Cardiology AF management guidelines include a safety‐based algorithm for selection of AAD therapy. Class 1C agents are recommended as first‐line therapy in patients without or with minimal structural heart disease. However, market research and clinical study data indicate a growing use of class III agents (mainly amiodarone) despite long‐term safety and tolerability concerns, suggesting that clinical practice does not adhere to current guidelines.
Keywords: antiarrhythmic drugs, class IC drugs, propafen‐one sustained release, Rhythmol SR Atrial Fibrillation Trial, structural heart disease, amiodarone
Full Text
The Full Text of this article is available as a PDF (41.6 KB).
References
- 1. Falk RH: Atrial fibrillation. N Engl J Med 2001; 344: 1067–1078 [DOI] [PubMed] [Google Scholar]
- 2. The Atrial Fibrillation Follow‐up Investigation of Rhythm Management (AFFIRM) Investigators : A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825–1833 [DOI] [PubMed] [Google Scholar]
- 3. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma Said SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ: Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group: A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834–1840 [DOI] [PubMed] [Google Scholar]
- 4. Prystowsky EN, Margiotti R, Fogel R, Evans JJ, Freedberg N, Shaar C: Atrial fibrillation with and without heart disease: Clinical characteristics and proarrhythmic risk (abstr 1109). Circulation 1996. (suppl 8); 94: 1 8964107 [Google Scholar]
- 5. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Hal‐perin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG, Gibbons RJ, Antman EM, Alpert JS, Faxon D, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC Jr, Klein WW, Alonso‐Garcia A, Blomstrom‐Lundqvist C, de Backer G, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation); North American Society of Pacing and Electrophysiology: ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation: Areport of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation). Circulation 2001; 104: 2118–2150 [PubMed] [Google Scholar]
- 6. Pritchett EL, Page RL, Carlson M, Undesser K, Fava G; Rythmol Atrial Fibrillation Trial (RAFT) Investigators: Efficacy and safety of sustained‐release propafenone (propafenone SR) for patients with atrial fibrillation. Am J Cardiol 2003; 92: 941–946 [DOI] [PubMed] [Google Scholar]
- 7. Torp‐Pedersen C, Moller M, Bloch‐Thomsen PE, Kober L, Sandoe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ: Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 1999; 341: 857–865 [DOI] [PubMed] [Google Scholar]
- 8. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN, for the Department of Veterans Affairs CHF‐STAT Investigators : Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: Observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF‐STAT). Circulation 1998; 98: 2574–2579 [DOI] [PubMed] [Google Scholar]
- 9. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling C, Lazzeri D: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia: Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995; 333: 77–82 [DOI] [PubMed] [Google Scholar]
- 10. Julian DG, Jackson FS, Szekely P, Prescott RJ: Acontrolled trial of sotalol for 1 year after myocardial infarction. Circulation 1983; 67: 161–162 [PubMed] [Google Scholar]
- 11. Kober L, Bloch Thomsen PE, Moller M, Torp‐Pedersen C, Carlsen J, Sandow E, Egstrup K, Agner E, Videbaek J, Marchant B, Camm AJ, Danish Investigations of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group : Effect of dofetilide in patients with recent myocardial infarction and left‐ventricular dysfunction: A randomized trial. Lancet 2000; 356: 2052–2058 [DOI] [PubMed] [Google Scholar]
- 12. Cardiac Arrhythmia Suppression Trial (CAST) Investigators : Preliminary report: Effects of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406–412 [DOI] [PubMed] [Google Scholar]
- 13. Teo KK, Yusuf S, Furberg CD: Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. J Am Med Assoc 1993; 270: 1589–1595 [PubMed] [Google Scholar]
- 14. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE: Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The An Ticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J Am Med Assoc 2001; 285: 2370–2375 [DOI] [PubMed] [Google Scholar]
- 15. Zimetbaum P, Ho KK, Olshansky B, Hadjis T, Lemery R, Friedman PA, Cannom DS, Chen XH, Josephson ME, FRACTAL Investigators : Variation in the utilization of antiarrhythmic drugs in patients with new onset atrial fibrillation. Am J Cardiol 2003; 91: 81–83 [DOI] [PubMed] [Google Scholar]
- 16. The AFFIRM Investigators : Atrial Fibrillation Follow‐up Investigation of Rhythm Management. Baseline characteristics of patients with atrial fibrillation: The AFFIRM study. Am Heart J 2002; 143: 991–1001 [DOI] [PubMed] [Google Scholar]
- 17. IMS : NPA Audit, 2004.
- 18. Fang MC, Stafford RS, Ruskin JN, Singer DE: National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med 2004; 164: 55–60 [DOI] [PubMed] [Google Scholar]
- 19. Heart Rhythm Society : Heart Rhythm Foundation Rx Survey. Current Usage of Cardiac Drugs. August 2004.
- 20. Vorperian VR, Havighurst TC, Miller S, January CT: Adverse effects of low dose amiodarone: Ameta‐analysis. J Am Coll Cardiol 1997; 30: 791–798 [DOI] [PubMed] [Google Scholar]
- 21. Kochiadakis GE, Igoumenidis NE, Hamilos MI, Tzerakis PG, Klapsinos NC, Zacharis EA, Vardas PE: Long‐term maintenance of normal sinus rhythm in patients with currently symptomatic atrial fibrillation: Amiodarone vs. propafenone. Both in low doses. Chest 2004; 125: 377–383 [DOI] [PubMed] [Google Scholar]
- 22. Connolly SJ: Evidence‐based analysis of amiodarone efficacy and safety. Circulation 1999; 100: 2025–2034 [DOI] [PubMed] [Google Scholar]
- 23. Siddoway LA: Amiodarone: Guidelines for use and monitoring. Am Fam Physician 2003; 68: 2189–2196 [PubMed] [Google Scholar]
- 24. Raeder EA, Podrid PJ, Lown B: Side effects and complications of amiodarone therapy. Am Heart J 1985; 109: 975–983 [DOI] [PubMed] [Google Scholar]
- 25. Jafari‐Fesharaki M, Scheinman MM: Adverse effects of amiodarone. Pacing Clin Electrophysiol 1998; 21: 108–120 [DOI] [PubMed] [Google Scholar]
- 26. Holmes JS, Shevrin M, Goldman B, Share D: Translating research into practice: Are physicians following evidence‐based guidelines in the treatment of hypertension? Med Care Res Rev 2004; 61: 453–473 [DOI] [PubMed] [Google Scholar]
- 27. Aliyu ZY, Yousif SB, Plantholt K, Salihu HM, Erinle A, Plantholt S: Assessing compliance of cardiologists with the National Cholesterol Education Program (NCEP) III guidelines in the ambulatory setting. Lipids Health Dis 2004; 12: 3: 9 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Nair A, Hazell W, Sutton T, Pillai S: Antithrombotic therapy in atrial fibrillation: An assessment of compliance with guidelines. N Z Med J 2005; 118: U1258 [PubMed] [Google Scholar]
- 29. Komajda M, Lapuerta P, Hermans N, Gonzalez‐Juanatey JR, van Veldheuisen GJ, Erdman E, Tavazzi L, Poole‐Wilson P, Le Pen C: Adherence to guidelines as a predictor of outcomein chronic heart failure: The MAHLER survey. Eur Heart J 2005; 26: 1653–1659 [DOI] [PubMed] [Google Scholar]